Skip to content

Extended Tricyle Project Indonesia for Extended-spectrum Beta-lactamase Positive Klebsiella Pneumoniae and Escherichia Coli

Extended Tricyle Project Indonesia for Extended-spectrum Beta-lactamase Positive Klebsiella Pneumoniae and Escherichia Coli

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07106944
Acronym
E-Trike
Enrollment
100
Registered
2025-08-06
Start date
2025-08-11
Completion date
2026-04-30
Last updated
2025-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carriage of ESBL-positive Escherichia Coli, Carriage of ESBL-positive Klebsiella Pneumoniae

Keywords

ESBL, carriage, Escherichia coli, Klebsiella pneumoniae, One Health

Brief summary

In 2019, Indonesia's first WHO Tricycle Project revealed alarming rates of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli across various sectors. The study found ESBL-producing E. coli in 40% of pregnant women, 57.7% of E. coli-induced bloodstream infections, 67.1% of broiler chicken, and 12.8% of total E. coli in water samples. In the first National Action Plan on Antimicrobial Resistance from Indonesia, the reduction of ESBL was identified as a clear goal. In E-Trike, Tricycle will be repeated, using the same methodology, to determine if a reduction has been achieved. Additionally, ESBL-positive Klebsiella pneumoniae will be included, as important pathogen for humans.

Detailed description

Antimicrobial resistance (AMR) is a global threat and is considered to be a silent pandemic. It is estimated that in 2021, over 4.71 million deaths were associated with AMR, with 1.14 million attributed to AMR. In 2020, the World Health Organization (WHO) Global Antimicrobial Resistance and Use Surveillance System (GLASS) reported the prevalence of cefotaxime-, ceftriaxone, and ceftazidime-resistant Klebsiella pneumoniae from bloodstream infections in South Asian region was 75.9%, 77.4%, 74.8%, respectively. Based on the report from the Indonesian Society for Clinical Microbiologists in 2023, the prevalence of third-generation cephalosporin-resistant Klebsiella pneumoniae in Indonesia was 57%, while third-generation cephalosporin-resistant E. coli was 68%. The WHO has been at the forefront of AMR through its Global Surveillance extended-spectrum beta-lactamase (ESBL)-positive E. coli Tricycle Project, which employs a One Health approach. This innovative surveillance program aims to obtain a comprehensive picture of AMR in humans, animals, and the environment, particularly in countries with limited surveillance capabilities. Indonesia's first pilot Tricycle Project revealed alarming rates of ESBL-producing E. coli across various sectors. The study found ESBL-producing E. coli in 40% of pregnant women, 57.7% of E. coli-induced bloodstream infections, 67.1% of broiler chicken, and 12.8% of total E. coli in water samples. These findings underscore the worrisome pattern of AMR in Indonesia and highlight the urgent need for expanded surveillance and control strategies. Klebsiella pneumoniae is the second most common Enterobacterales found in humans; its role in animals and the environment is less clear, even more in the Indonesian setting. A better understanding of the presence of this human pathogen in other domains is needed, so that effective intervention strategies on AMR for the Indonesian situation can be designed. In E-Trike, the original WHO Tricycle protocol (which already includes sample size calculation) will be used, with three modifications: 1. ESBL-K. pneumoniae (ESBL-Kp) will be included for all samples. Additionally, from pregnant women, not only rectal samples will be taken, but also throat samples, as previously it was shown that 15% of adults carry Kp in their throat in Indonesia. 2. In addition to the MacConkey agar supplemented with cefotaxime, CHROMagar plates will be used. 3. The sampling period will only be 5 months, instead of the 10 months that was used in the 2019 Tricycle. However, both wet and dry months will be included. Primary aims: * To determine the prevalence of ESBL-producing E. coli (ESBL-Ec) in humans (hospital and community), the food chain (animals), and the environment. * To determine the prevalence of ESBL-producing Klebsiella pneumoniae (ESBL-Kp) in humans (hospital and community), the food chain (animals), and the environment. Secondary aims: * To compare the yield of the ESBL Chromagar™ plate compared to the MacConkey agar plate supplemented with 4 mg/L cefotaxime. * To assess the susceptibility of the ESBL-Ec and ESBL-Kp to carbapenem antibiotics and other relevant classes of antibiotic. * To understand the resistance mechanisms of ESBL-Ec and ESBL-Kp isolates using genomic analysis. Setting The study will be performed in Jakarta, Indonesia. Surveillance in humans will include: Community: rectal and throat carriage in pregnant women in 3 puskesmas. From Hospitals: bloodstream infections with E. coli and K. pneumoniae, Cipto Mangunkusumo Hospital and Persahabatan Hospital; isolates will be included Surveillance in food chain will include: Chicken caeca from the live bird open market and slaughterhouse in Jakarta Surveillance in the environment will include: River water upstream and downstream, animal slaughter wastewater, human communal wastewater

Interventions

OTHERCommunity pregnant women: rectal and throat swab

Community pregnant women: rectal and throat swab

Sponsors

Dr. Sulianti Saroso Hospital, Jakarta
CollaboratorUNKNOWN
Universitas Indonesia, Cipto Mangunkusumo National General Hospital
CollaboratorUNKNOWN
RSUP Persahabatan Hospital, Jakarta, Indonesia
CollaboratorUNKNOWN
National Institute for Public Health and the Environment (RIVM)
CollaboratorOTHER_GOV
Utrecht University
CollaboratorOTHER
Erasmus Medical Center
Lead SponsorOTHER

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* pregnant women at antenatal visits

Exclusion criteria

* no informed consent

Design outcomes

Primary

MeasureTime frame
Number of pregnant women in the community in Jakarta that carry ESBL-positive E. coli / Klebsiella pneumoniae in their rectum or throatJuly 2025-March 2026
Number of ESBL-positive E. coli/K. pneumoniae among all blood cultures taken / all E. coli/K. pneumoniae from blood culturesJuly 2025 - March 2026
Prevalence of ESBL-Ec and ESBL-Kp in the food chain (chicken) in Jakarta, IndonesiaJuly 2025 - March 2026
Prevalence of ESBL-Ec and ESBL-Kp in the environment (water) in Jakarta, IndonesiaJuly 2025 - March 2026

Secondary

MeasureTime frame
Number of ESBL-Ec and ESBL-Kp found in the study with resistance to carbapenem antibiotics and other relevant classes of antibiotic.July 2025 - March 2026
The prevalence of ESBL resistant genes among the ESBL-Ec and ESBL-Kp isolates found in the study based on genomic analysis.July 2025-March 2026
Number of ESBL-Ec and ESBL-Kp (yield) found using the ESBL Chromagar™ plate compared to the MacConkey agar plate supplemented with 4 mg/L cefotaxime per human subject or chicken or environmental sample included.July 2025-March 2026

Contacts

Primary ContactJuliëtte A. Severin, MD PhD
fleming.fellowship@erasmusmc.nl; j.severin@erasmusmc.nl0031-(0)10-7033510

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026